BOME Pharma builds its mission around a hard reality: infectious diseases continue to strain global health systems, economies, and population stability. COVID-19, tuberculosis, malaria, and influenza remain among the leading causes of illness and death worldwide.

The company also applies its research to cancer immunology, where immune recognition follows similar biological pathways.

Each disease presents unique challenges, from viral mutation and immune escape to hidden infections and constantly changing antigens. Together, they highlight a common limitation in current prevention strategies: while existing vaccines are highly effective, they do not always generate consistent immune responses across populations or against rapidly evolving pathogens.

This challenge drives BOME Pharma’s focus on infectious disease vaccine innovation, global health innovations, and advanced disease prevention platforms designed to strengthen immune recognition from the earliest stages of antigen exposure.

Readers exploring related foundations can read our hub article “Transforming Allergy Treatment Through Innovation at BOME Pharma” and review Immune System Basics and Vaccine Development Overview for background context.

BOME Pharma’s Antigen Delivery by Precipitation (ADBP) platform focuses on how structured particulate antigen delivery influences immune activation at the cellular level. Immune response begins when antigen-presenting cells (APCs), including dendritic cells and macrophages, encounter foreign antigens.

The quality of this interaction determines downstream immune strength.

ADBP improves this process by forming particles within a biologically relevant size range that aligns with natural APC uptake pathways. Immune cells evolved to internalize structures between 0.5–5 microns, making this range highly efficient for antigen processing.

Key immune mechanisms supported by ADBP include enhanced antigen uptake by APCs, increased antigen load per immune cell, enhanced MHC I and MHC II presentation, stronger T cell activation signaling, and improved coordination between innate and adaptive immunity.

A little bit about the evolution of the enhanced APC uptake of particles in the 0.5-to-5-micron size range. It was originally developed by free-living amoeba as a feeding mechanism and later adapted by APCs, which move through tissues in an amoeba-like manner  by pushing and pulling their whole selves through finger-like processes they extend out from their current locations, as a way to pick up particles that might not belong in the tissues they traverse and bring them to lymph nodes for immune system processing which, if the signal is strong enough, can result in immunomodulation.

Readers can explore Antigen Presentation Pathways and Adaptive Immune Activation for deeper context.

COVID-19
COVID-19 vaccine research now focuses on variant resilience and immune durability. ADBP-based particulate delivery may improve immune recognition of conserved immunogenic viral peptide epitopes and strengthen cross-reactive T cells and antibody responses against evolving strains.

Tuberculosis (TB)
TB requires strong Th1 and Th17 immune responses along with durable lung-resident immunity. Mycobacterium tuberculosis naturally interacts with phagocytic immune cells. ADBP’s particulate size range aligns with this pathway, supporting improved antigen processing and immune activation consistency.

Malaria
Malaria vaccines aim to generate strong antibody responses and CD8 T cell activity targeting liver-stage infection. ADBP supports higher antigen density per APC and improved germinal center activity, which strengthens antibody affinity maturation.

Influenza
Influenza requires broad immune coverage due to rapid antigenic evolution. ADBP may improve immune breadth by increasing APC antigen loading and strengthening T follicular helper cell responses, supporting longer-lasting antibody protection.

Cancer (Immunotherapy Context)
Cancer immunotherapy relies on immune recognition of abnormal cellular markers. While not infectious, the same antigen presentation pathways apply. ADBP may support improved immune targeting of tumor-associated antigens in research contexts.

Across all five areas, the shared challenge is improving antigen presentation efficiency at the point of first immune encounter.

Readers may connect this section with Tumor Immunology Principles and Vaccine Platform Technologies for cross-domain understanding.

Vaccine development follows a structured regulatory pathway involving preclinical research, clinical trials, manufacturing validation, and regulatory review. Each stage ensures safety, reproducibility, and immune consistency.

BOME Pharma’s current focus is validation of the ADBP platform within its lead indication program. Broader applications across infectious diseases and oncology remain future development pathways dependent on regulatory approval.

The company may engage external collaborators in the fields of synthetic peptide chemistry, immunology, microbiology of infectious diseases and cancer immunotherapy.

Key milestones include preclinical immune mechanism validation, demonstration of safety and reproducibility, clinical evaluation of immune activation outcomes, manufacturing scale-up for consistent particle formation, and FDA regulatory review.

Future development opportunities may include multi-antigen formulations, expanded disease targets, and broader immune applications following approval.

Readers can explore FDA Clinical Trial Phases and Biologics Manufacturing Standards for additional regulatory insight, while continuing with Investing in Global Health: The Economic Case for ADBP Vaccines.

Investment plays a critical role in advancing vaccine platforms from research to validated medical systems. Infectious disease prevention requires long timelines, specialized infrastructure, and sustained capital support.

ADBP aligns with long-term investment models because it functions as a platform technology with a broad range of applications in addition to a launch product already proven safe and effective with a ready market of 11 to 18 million chronically symptomatic Americans eager for relief and no competition. Platform systems can expand across multiple disease categories once validated.

Investment priorities include scaling particulate manufacturing systems, supporting clinical validation programs, advancing regulatory readiness, expanding post-approval applications, and improving global access to scalable vaccine technologies.

Global interest continues to grow in Disease Prevention Solutions, Global Health Innovations, and platform-based immune technologies capable of addressing multiple infectious threats.

You can also return to Transforming Allergy Treatment Through Innovation at BOME Pharma to learn how ADBP supports BOME Pharma’s long-term vision.

BOME Pharma advances ADBP development through integrated scientific, operational, and manufacturing leadership.

Robert E. Coifman, MD, Founder and Chief Science Officer, leads scientific direction and platform strategy development. His work focuses on immune system engineering and translational vaccine design.

Eric Feerst, COO and Project Manager for Quality Control and Regulatory Affairs, oversees operational execution and ensures regulatory alignment across development pathways.

Millan Bhatt, Chief Product Officer, leads aseptic GMP packaging and manufacturing readiness to support scalable and controlled production systems.

This structure ensures coordination between scientific innovation, regulatory compliance, and manufacturing execution across all development stages.

ADBP represents a platform approach to improving immune system engagement through structured antigen delivery. By optimizing how antigen-presenting cells encounter and process particulate antigens, the technology strengthens early immune signaling that helps shape adaptive immune responses.

Global infectious diseases continue to demand better vaccine technologies capable of addressing COVID-19, tuberculosis, malaria, influenza, and future cancer immunotherapy applications. Although each disease presents unique challenges, they all depend on efficient antigen presentation and coordinated immune activation.

BOME Pharma continues advancing ADBP through rigorous scientific research and carefully defined FDA development pathways. The company’s current priority remains successful regulatory validation before pursuing broader collaborations or expanded applications.

ADBP demonstrates how a single immune platform may support future advances across multiple disease categories.

To continue learning about BOME Pharma’s vision for immune innovation, explore Transforming Allergy Treatment Through Innovation at BOME Pharma. You can also continue with The Global Impact of Infectious Diseases: Why We Need Better Vaccines, ADBP and COVID-19: A New Frontier in Vaccine Development, or Tackling Tuberculosis with ADBP: The Science and Potential.

For additional information about BOME Pharma, future developments, and the ADBP platform, contact info@bomepharma.com or visit https://bomepharma.com/.